Stockreport

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymp...

Seagen Inc.  (SGEN) 
Last seagen inc. earnings: 4/30 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.seattlegenetics.com
PDF -Data Presented in Oral Session with Simultaneous Publication in The Lancet- -Randomized Phase 3 Clinical Trial Demonstrated ADCETRIS plus C [Read more]